This flu season has turned out to be quite a surprise. A new study from Cleveland Clinic indicates the 2024–2025 flu shot might have fallen short — and potentially worsened the situation. With vaccinated patients reportedly having higher infection rates, health professionals and the general public are now reassessing the vaccine's effectiveness in real life.

New research from the Cleveland Clinic has caused alarm among health professionals and the general public. In contrast to years of conventional wisdom, the current flu shot may not only have been useless — it could actually have made some people more susceptible to the flu.

Released as a preprint on MedRxiv.org, the Cleveland Clinic study compared infection rates among more than 53,000 of its own staff and concluded that vaccinated staff had a higher rate of flu infections than their unvaccinated peers. Although the study is not yet subject to peer review, early conclusions have sparked a firestorm of questions about vaccine effectiveness, public health policy, and efforts to prevent future influenza.

Carried out across 25 weeks of the 2024-2025 respiratory viral season, the study monitored flu infection rates among Cleveland Clinic staff — predominantly a cohort of healthy adults of working age.

• Vaccinated staff had a 27% higher rate of flu infections than the unvaccinated cohort.
• Effectiveness of the vaccine was estimated at -26.9%, reflecting not only diminished protection, but a seeming increase in risk.
• The rate of influenza initially tracked similarly in both groups, but increased more steeply in the vaccinated as the season went on.

Notably, almost 99% of the vaccinated workers got the trivalent inactivated influenza vaccine, so it is difficult to know whether other formulations of the vaccine might have produced different results.

What Does "Negative Vaccine Effectiveness" Really Mean?

Negative vaccine effectiveness — particularly in the range of -26.9% — is a dramatic and disconcerting statistic. Yet, it does not indicate the vaccine induces the flu. Rather, it suggests that in this specific season, the vaccine provided no significant protection and potentially was not well matched to the prevailing virus strains.

The Cleveland Clinic explained in a statement to Fox News Digital, "The results do not suggest that vaccination increases the risk of flu. Instead, the study implies that the effectiveness of this season's vaccine in preventing influenza may have been limited in relatively healthy healthcare workers."

That is to say, the virus could have caught up with the shot.

While the results are surprising, specialists point out that this study is far from being the last word regarding the effectiveness of flu shots. There were several limitations the authors have acknowledged:

The research did not test flu severity of symptoms, hospitalizations, or fatalities — which are important indicators of vaccine worth.

It tested only healthcare workers, but not children, elderly people, and immunocompromised individuals, who most usually benefit from flu vaccination.

The vast majority of participants were given one type of vaccine, so the performance of others remains unknown.

Dependence on home test kits could have resulted in underreporting or misclassification of certain cases.

Why the Flu Shot Works Differently Each Year?

Performance of flu vaccines differs from year to year because of a number of factors:

Strain Mismatch: Every year, vaccine manufacturers make an educated estimate of the most common flu strains. If they're incorrect, the vaccine will provide suboptimal protection.

Population Immunity: Immune response varies with age, health, and past experience with flu viruses or vaccines.

Mutation Rates: Flu viruses change rapidly. Even when production starts, strains can change, lowering efficacy.

This year could just have been an anomaly in terms of immune response or strain drift — but the stakes are high for how we handle flu vaccination in the future.

Physicians warn not to make quick judgments based on a single preprint study. Dr. [Name], infectious disease physician at [Institution], cautions:

While Cleveland Clinic research is definitely worth further examination, it's important to keep in mind that the flu vaccine's greatest aim is to curb severe illness and mortality. We just don't have enough data yet to realize the total effect of this year's vaccine.

The Centers for Disease Control and Prevention (CDC) still encourages yearly flu vaccination for all people six months and older based on long-standing proof that flu vaccinations decrease the possibility of serious complications from the flu.

Should You Still Get the Flu Shot?

The quick answer: Yes — but with awareness.

This study points out that flu vaccine effectiveness can vary, and in extreme cases, may even not protect as expected. But overall evidence still continues to affirm the vaccine's function of reducing hospitalizations, decreasing duration of illness, and safeguarding high-risk groups.

If anything, the results emphasize the importance of ongoing investment in the development of vaccines, improved real-time surveillance of viral mutations, and open reporting of vaccine performance.

The Cleveland Clinic study doesn't mark the end of the flu shot — but it does pose important questions about how we produce, test, and present vaccine effectiveness. As more evidence comes in and peer-reviewed evaluation is finalized, health authorities will most likely fine-tune their approach to prevent future flu seasons from catching us unprepared.

Cancer is an umbrella term for abnormal excess growth that can occur in any part of the body. Leukemia is the cancer of blood, which means there is rapid growth of abnormal blood cells. This growth starts in the bone marrow, which is where your body makes blood. The Cleveland Clinic explains that unlike other cancers, leukemia does not form a mass or tumor that can be detected in a CT scan.

The usual treatment of Leukemia involves Chemotherapy, whether by pill, injection into your vein or a shot under your skin. Another treatment for it is immunotherapy which uses a drug to boost your body’ defense system so that it can fight the cancer itself. Now, a research by American Association for Cancer Research April 2025, has revealed that a pre-made version of immunotherapy can effectively fight blood cancers. This "off-the-shelf" approach offers a potentially faster and easier way to deliver this powerful therapy to patients in need.

Promising Treatment Against Blood Cancer

This new way to treat blood cancer uses special immune cells called natural killer cells, or NK cells. These NK cells have been changed in a lab to have special tools, called CARs, that help them find and kill cancer cells. What's really helpful is that these CAR NK cells can be made ahead of time from healthy people and stored. This means doctors can just take them off the shelf and give them to patients who need them quickly, without having to wait for a treatment to be made just for them, making the whole process much simpler and faster.

The results from using this ready-made CAR NK cell treatment yielded promising results, especially for people with a type of blood cancer called acute myeloid leukemia, or AML. The scientists found that after getting this treatment, some of the patients with AML had their cancer completely disappear. This is called complete remission, and it means there were no signs of cancer left in their blood. These early successes give a lot of hope for a new and better way to treat this difficult disease.

Notably, AML is a very fast-growing and serious cancer. According to American Cancer Society this cancer develops in the myeloid cell, the cells that would normally become white blood cells. This type of cancer develops quickly, hence needs to be treated with the same urgency.

Who Does This Treatment Help?

The first group of patients who received this ready-made CAR NK cell treatment were people whose leukemia had either stopped responding to other treatments or had come back after treatment. These are often the most difficult cases to treat. The fact that some of these patients had such a good response to the SENTI-202 treatment, which is a safety feature to the SENTI-202 cells. It's like a special switch that stops the NK cells from attacking healthy cells in the body. With their cancer completely disappearing, is a very encouraging sign that this new approach could offer hope to patients who have run out of other options.

More Research Needed To Confirm Safety and Effective

The researchers are hopeful about the new treatment and early success for the treatment. They believe that this ready-made approach could lead to new types of immune therapies that are much easier to produce and give to patients. Researchers emphasized that there's a big need for better treatments for AML, and he hopes this new method can become an important option for these patients who often have very limited choices.

It's important to remember that these are just the first results from an ongoing study. The scientists are still enrolling more patients to learn even more about how safe and how well SENTI-202 works. They need to keep studying it to make sure it's a reliable and effective treatment for more people with blood cancers. Before this treatment can be used widely, the findings need to be carefully reviewed and published in a scientific journal.

The uncertainty around the Novavax's COVID-19 vaccine has been exacerbated by the Trump administration. The new government has imposed new requirements on the nation's only traditional protein-based vaccine. These new requirements have led to many confusions about vaccine updates, including other vaccines too, which await approval.

The Wait For Full Approval Is Too Long

Novavax is the maker of the protein-based COVID-19 vaccine, which was on track to receive full approval from the US Food and Drug Administration (FDA) by April 1. However, the approval process was paused because of Dr Sara Brenner, the FDA's acting commissioner. The reason for delay has raised many questions about the interference, including political, especially after Dr Peter Marks, FDA's longtime vaccine chief had left following disagreements with Health Secretary Robert F Kennedy Jr. These events have further led to the apprehensions of uncertainty regarding the vaccine's future.

As of now, Novavax's vaccine is only authorized for emergency use. Unlike mRNA vaccines form Pfizer and Moderna, which have full approval, the Novavax vaccine holds the EUA or the Emergency Use Authorization, which allows it to be distributed during public health emergencies. However, once the emergency ends, the FDA can remove these vaccines from market unless full approval is granted.

What Caused The Delay?

The FDA had initially planned to approve Novavax's vaccine by its April 1 target date. However, sources familiar with the situation revealed that Trump appointees influenced the delay. Since then, Novavax has been in discussions with the FDA to determine additional requirements for approval. In the meantime, the FDA's recent comments have fueled concerns that Novavax’s vaccine may be treated as a “new product” due to its updates to match last year’s coronavirus strain. This would require new clinical trials, a process unlikely to be completed before the fall.

ALSO READ: Novavax Says FDA Approval Back on Track for Its COVID Vaccine

This approach to Novavax’s vaccine approval stands in stark contrast to the FDA’s treatment of the mRNA vaccines, where annual strain updates have been handled in a way similar to flu vaccines, requiring only small-scale tests to demonstrate the vaccine’s continued effectiveness against new strains. Dr. Paul Offit, a vaccine expert, argued that it would be unnecessary to treat these annual updates as “new products” requiring full trials, as long as the updated vaccines show that they produce protective antibody levels.

Role Of HHS Secretary

Of course Robert F Kennedy Jr will have a role to play, being the Health Secretary, and a known vaccine skeptic. Despite claiming in recent speeches that he is not anti-vaccine, Kennedy’s past associations with anti-vaccine groups have raised alarms. His nonprofit, Children’s Health Defense, has been involved in campaigns questioning vaccine safety, and Kennedy himself has made public statements suggesting that vaccines can cause autism—a long-debunked claim.

His actions have also contributed to the uncertainty that surrounds the Novavax's approval today and the overall direction of US vaccine policies.

Is Novavax Different From Other Vaccines?

What sets Novavax apart from other COVID-19 vaccines is its traditional approach. While Pfizer and Moderna’s mRNA vaccines use genetic instructions to create a temporary version of the virus’ spike protein, Novavax’s vaccine contains lab-grown copies of the spike protein itself. This approach has been used for decades in vaccines for diseases like hepatitis B and shingles, making it a more familiar method for people who may be hesitant about mRNA vaccines.

Danish multinational pharmaceutical company Novo Nordisk has launched Wegovy in Thailand, marking the entry of its hugely popular weight loss drug in Southeast Asian market. First launched in 2021, Wegovy helped make Novo Nordisk Europe's most valuable listed company until recently, worth $615 billion at its peak. Wegovy is a semaglutide shot, which means that it is a GLP-1 receptor agonist.

"We actually received the Thai FDA approval already in 2023," said Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary. He noted that Novo was making Wegovy available in Thailand ahead of rival Eli Lilly's Zepbound. Wegovy is currently available for prescription in private hospitals around the country and will be available soon in public hospitals. Notably, Bruland declined to provide details on Wegovy's pricing in Thailand, which has a population of around 66 million, or Novo Nordisk's plans for expansion into other Southeast Asian markets.

Notably, the most popular GLP-1 agonist Ozempic was also created by Novo Nordisk. Earlier this month, the pharma giant expanded its research in the field diabetes and weight loss drug and announced that its diabetes pill, Rybelsus, demonstrated cardiovascular benefits in a late-stage trial. The findings pave the way for the medication to become a new treatment option for people living with both diabetes and heart disease.

How Do Semaglutides Work?

Semglutide is the synthetic version of GLP-1—a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called Post nutrition hormones, and help you absorb the energy you just consumed.

GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. Ozempic imitates this hormone, thereby, silencing the food chatter in the brain. Interestingly, for some people this food chatter is really quiet ( people with low appetite) and for others it is an outbrurst, (people who generally binge eat.) So with Ozempic, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.

However, it is important to note that losing weight includes not just fat but muscle as well. Losing too much muscle can lead to reduced strength and a shorter life span. Notably, records show that most people who start taking them stop it at 12 weeks; therefore, it is important for some but not for others.

Notably, last month, US pharma major Eli Lilly launched the obesity management drug Mounjaro in India at one-fifth of the US price. The company rolled out the drug in a single-dose vial following the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO). It has been priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial. "It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors," the company said.